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Abstract 
This study was to investigate the antimicrobial resistance of Enterobacter cloacae isolated in 8 consecutive years in 
the First Bethune Hospital. Disk diffusion test was used to study the antimicrobial resistance. The data were analyzed 
by WHONET 5 software according to Clinical and Laboratory Standards Institute (CLSI). Most of 683 strains of 
Enterobacter cloacae were collected from sputum 410 (60.0%), secretions and pus 105 (15.4%), urine 69 (10.1%) 
during the past 8 years. No Enterobacter cloacae was resistant to imipenem and meropenem in the First Bethune 
Hospital. The antimicrobial resistance of Enterobacter cloacae had increased in recent 8 years. The change of the 
antimicrobial resistance should be investigated in order to direct rational drug usage in the clinic and prevent bacterial 
strain of drug resistance from b eing transmitted. 
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1.Introduction 
Enterobacter cloacae is commonly encountered as a nosocomial pathogen[1] and is therefore under 
intensive selective pressure from broad-spectrum -lactam usage. It is the most commonly isolated 
member of the Enterobacteriaceae. The seriousness of multi-resistant Enterobacter cloacae can vary 
markedly worldwide and within nations. The objectives of this study were to investigate the antimicrobial 
resistance of Enterobacter cloacae isolated in 8 consecutive years in the First Bethune Hospital. 
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2.Materials and methods 
2.1.Bacterial isolates 
683 Consecutive nonduplicate nosocomial isolates of Enterobacter cloacae were collected during the 
period from 2003 to 2010 in the First Bethune Hospital. Isolates were identified at the species level using 
standard biochemical tests and microbiological methods. 
2.2.Antimicrobial susceptibility testing 
The susceptibilities of Enterobacter cloacae to 17 antimicrobial agents were determined by the disk 
diffusion method in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines. 
3.Results 
Distribution of specimen type: during the 8-year study period, 683 consecutive clinical isolates of 
Enterobacter cloacae were isolated in the First Bethune Hospital. The strains were cultured from sputum 
410 (60.0%), secretions and pus 105 (15.4%), urine 69 (10.1%), blood 50 (7.3%), pleural fluid and 
abdominal fluid 30 (4.4%), others 19 (2.8%). 
No Enterobacter cloacae was resistant to imipenem and meropenem in the First Bethune Hospital. 
The resistance of Enterobacter cloacae is shown in table 1. 
4.Discussion 
Enterobacter cloacae are significant causes of nosocomial infections. The top three specimen types in 
the present study were sputum, secretions and pus, urine in the past 8 years in the First Bethune Hospital. 
It is emphasized that Enterobacter cloacae are mainly responsible for pneumonia, wound infection and 
urinary tract infection in the First Bethune Hospital. 
Enterobacter cloacae are intrinsically resistant to aminopenicillins, cefazolin, and cefoxitin due to the 
pro -lactamases. Moreover, ESBL-producing Enterobacter 
cloacae have been identified in the United States[2] and Europe[3], and carbapenems are considered the 
drug of choice in these cases. The resistance rates of Enterobacter cloacae for peperacillin, 
ticarcillin/clavulanic acid, cefoxitin, cefuroxime sodium, trimethoprim/sulfamethoxazole, cefotaxime and 
ceftriaxone were almost more than 60%, however, in addition to excellent activity of imipenem and 
meropenem, the resistance rates for piperacillin/tazobactam, cefepime, cefoperazone/sulbactam, amikacin, 
ciprofloxacin, levofloxacin and gatifloxacin were shown a relative low during 8 years in the First Bethune 
Hospital. It is associated with different geography, breakpoints, or antimicrobial susceptibility testing. 
-lactamase is a type of cephalosporinase and its gene is usually located in the chromosomes 
-lactam inducers can raise its level of 
expr -lactamases 
-lactamases (Ambler classification)[4]. AmpC enzyme can 
hydrolyze third generation cephalosporins and is not affected -lactamase inhibitors. The level of 
- -lactams are a type of pentapeptide analogue that can 
activate hydrolases of cell walls to cause synthetic disturbances of peptidoglycan, so that the expression 
of amp -lactamases. They 
-lactamase inhibitors can affect 
them. Because the properties of these two enzymes are different, different antimicrobial agents should be 
selected to kill bacteria producing different types of enzymes. Therefore, it is very important to eliminate 
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the rates of AmpC enzymes and ESBLs, which are both produced in Enterobacter cloacae, and have 
important significance in the application of clinical antimicrobial agents[5].  
The drug resistant status of Enterobacter cloacae is severe. Reasonable use of the third generation 
cephalosporins may be the key to reduction of stably derepressed strains. Monitoring antibiotic use with 
microbiology laboratory support can promote rational drug utilization, cut costs and delay the emergence 
of resistant organisms. 
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Table 1   Antimicrobial resistance of enterobacter cloacae (%)

 
Antibiotics 
2003(n=
39) 
2004(n=
42) 
2005(n=
47) 
2006(n=
46) 
2007 
(n=58) 
2008 
(n=121) 
2009 
(n=152) 
2010 
(n=178) 
Piperacillin 51.3 57.1 63.8 73.9 72.4 70.2 75.7 78.7 
Ticarcillin/Clavulanic acid 41.0 52.3 61.7 71.7 74.1 70.2 72.4 75.3 
Piperacillin/Tazobactam 17.9 21.4 23.4 28.3 24.1 28.9 30.3 33.7 
Cefoperazone/Sulbactam 20.5 23.8 25.5 39.1 31.0 32.2 33.6 36.0 
Cefoxitin 94.9 95.2 95.7 95.6 96.6 95.9 96.1 97.2 
Cefuroxime sodium 51.3 57.1 63.8 78.3 74.1 79.3 82.2 81.5 
Imipenem 0 0 0 0 0 0 0 0 
Meropenem 0 0 0 0 0 0 0 0 
Ceftazidime 33.3 38.1 42.6 47.8 50.0 50.4 52.6 54.5 
Cefotaxime 41.0 42.9 51.1 54.3 55.2 62.0 65.1 71.3 
Ceftriaxone 41.0 42.9 51.1 56.5 55.2 61.2 65.8 71.9 
Cefepime 15.4 16.7 17.0 28.3 24.1 32.2 34.2 36.0 
Amikacin 5.1 9.5 12.8 23.9 27.6 30.6 31.6 33.7 
Ciprofloxacin 17.9 19.0 21.3 23.9 31.0 34.7 36.2 39.3 
Levofloxacin 15.4 16.7 17.0 19.6 20.7 21.5 22.4 24.7 
Gatifloxacin 10.3 11.9 12.8 15.2 19.0 19.0 21.1 21.9 
Trimethoprim/Sulfamethoxazol
e 
51.3 57.1 
63.8 
69.6 72.4 66.1 72.4 75.3 
